Vascular Health and Risk Management · 2022 · 54 citations · 27 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyMedical GeneticsCardiovascular Drug SafetyDyslipidemia ManagementFamilial HypercholesterolemiaLipid ManagementLipid-lowering TherapyLipoprotein MetabolismAutosomal Dominant InheritanceCardiovascular Disease ManagementHomozygous Familial HypercholesterolemiaLdl Cholesterol LoweringLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionProtein Translation ControlSerious Adverse Events
Familial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. In this review, we discuss its mechanism, current evidence, limitations of use including adverse events, and impact on health-related quality of life.
27
Frederick J. Raal, Raúl D. Santos, Dirk Blom et al. · The Lancet · 2010 · 906 citations
Marina Cuchel, Emma A. Meagher, Hendrik du Toit Theron et al. · The Lancet · 2012 · 740 citations · Full text
John J.P. Kastelein, Mark K. Wedel, Brenda F. Baker et al. · Circulation · 2006 · 357 citations · Full text
Gregory S. Thomas, William C. Cromwell, Shariq Ali et al. · Journal of the American College of Cardiology · 2013 · 246 citations